Human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC) are molecular breast cancer subtypes that exhibit higher BM propensities than hormone receptor (HR)-positive breast cancer [1,3]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.